MOL 4239

Drug Profile

MOL 4239

Alternative Names: MOL4239; WP 1220

Latest Information Update: 15 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Dermin; Moleculin; Moleculin Biotech
  • Class Antipsoriatics; Cinnamates; Small molecules
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cutaneous T cell lymphoma
  • Discontinued Plaque psoriasis

Most Recent Events

  • 13 Jun 2017 Moleculin inends to file an IND application with the US FDA for Cutaneous T-Cell Lymphoma
  • 01 Feb 2016 Discontinued - Phase-II for Plaque psoriasis in USA (Topical)
  • 01 Feb 2016 Moleculin and Dermin plan a clinical trial for Cutaneous T-cell lymphoma (Early-stage disease) in Poland (Moleculin Form S-1, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top